US FDA approves Neurocrine ’s Ingrezza capsules to treat tardive dyskinesia

The US Food and Drug Administration (FDA) has approved Neurocrine Biosciences ’ Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia (TD).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news